KLOW blend
Also called GHK-Cu + BPC-157 + TB-500 + KPV
A four-ingredient research blend marketed for recovery, skin and inflammation. It is GLOW plus KPV. Studies of the individual ingredients do not establish benefits for the combined product.
Overview
What it is
One supplier lists an 80 mg vial as 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500 (listed as full-length thymosin beta-4) and 10 mg KPV. These are whole-vial totals; the GHK-Cu figure is the copper-peptide complex, not elemental copper.
How it works
KPV (lysine-proline-valine) enters gut and immune cells through the PepT1 transporter and reduced inflammatory signaling in lab cells. GHK-Cu, BPC-157 and TB-500 are covered in their own entries.
What the research shows
KPV given in drinking water reduced gut inflammation in two mouse colitis models. A topical GHK-Cu formulation improved wrinkle measures in 40 women over eight weeks. BPC-157 improved tendon healing in rats. None of these tested KLOW.
Studied for
- Gut inflammationKPV, mice
- Wrinklestopical GHK-Cu, small human study
- Tendon healingBPC-157, rats
Safety and regulatory status
Safety and side effects
No blend-specific side-effect data exist. In May 2026 the FDA reported no identified clinical studies or human exposure data for KPV by any route, with gaps on immune reactions and aggregation. Multi-ingredient products make it hard to tell which component causes a reaction.
Regulatory status
Not FDA approved. Compounded products are not FDA approved.
Mixing and dosing reference
Reference information only. Read before using this section.
KLOW (80 mg Blend) Dosage Protocol
- Vial
- 80 mg total blend 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 + 10 mg KPV
- Add diluent
- 3 mL
- Concentration
- 26.67 mg/mL
- 1 unit (U-100)
- 266.67 mcg total in 0.01 mL
- Route
- Subcutaneous
Standard / Gradual Approach
| Week | Daily Dose (per component) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | TB-500: 250 mcg | BPC-157: 250 mcg | KPV: 250 mcg | GHK-Cu: 1.25 mg | 7.5 units (0.075 mL) |
| Weeks 3–4 | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
| Weeks 5–8 | TB-500: 750 mcg | BPC-157: 750 mcg | KPV: 750 mcg | GHK-Cu: 3.75 mg | 22.5 units (0.225 mL) |
| Weeks 9–12 (Maintenance) | TB-500: 500 mcg | BPC-157: 500 mcg | KPV: 500 mcg | GHK-Cu: 2.5 mg | 15 units (0.15 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- A peptide protocol can only be compared with research when the compound, formulation, route, amount, frequency, duration, and population are sufficiently similar. The cited KPV studies include intestinal and orally targeted models, the BPC-157 evidence is predominantly preclinical, and the GHK-Cu and thymosin beta-4 literature spans multiple formulations and tissues. None reproduces the four-component vial or the exact blend dose per day displayed above.
- The chart is useful for one narrow purpose: it keeps the community-reported schedule and its syringe math auditable. At 3.0 mL final volume, 7.5 units equals 0.075 mL, 15 units equals 0.15 mL, and 22.5 units equals 0.225 mL. Because the blend ratio is fixed, each of those volumes delivers all four components together. That arithmetic does not establish safety, effectiveness, or an optimal cycle length.
- Readers comparing the dosing protocol should verify the vial composition, final volume, total concentration, amount of each component, U-100 units, mL, frequency, and phase duration in the same row. Omitting any one of those details makes a blend calculation difficult to interpret and increases the risk of confusing total blend mass with the mass of an individual peptide.
Protocol source: PeptideDosages.com
Common questions
Is KLOW better than GLOW?
No head-to-head comparison exists. Adding an ingredient does not prove an added benefit.
What is the difference between a blend and a stack?
A blend combines ingredients in one product; a stack uses separate products together. Neither term means the combination was tested.
Does KLOW help with fat loss?
The research does not establish that.
Related in Immune Health
Sources and further reading (5)
- Dalmasso G, et al. PepT1-mediated KPV uptake reduces intestinal inflammation. Gastroenterology, 2008.
- Badenhorst T, et al. GHK-Cu effects on collagen, elastin and wrinkle parameters. J Aging Sci, 2016.
- Staresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res, 2003.
- FDA. Evaluation of KPV-related bulk drug substances, May 12, 2026.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Laboratory research material: KLOW Research Use Only